SUZHOU, China and IRVINE, Calif., July 1, 2025 /PRNewswire/ — MedEdge Innovations (MEI), a leading developer of advanced medical materials and device technologies, today announced the official launch of its medical implant-grade expanded polytetrafluoroethylene (ePTFE) product line and comprehensive customized CDMO (Contract Development and Manufacturing Organization) services via a new digital platform: www.meimedtech.com.
This strategic expansion marks a major milestone in MEI’s ongoing mission to provide high-performance, customized medical solutions to device manufacturers worldwide.
Backed by more than a decade of innovation and engineering excellence, MEI leverages proprietary manufacturing processes and deep materials science expertise to deliver premium ePTFE components — including membranes, tubing, and ultra-thin tubing — tailored for cardiovascular, peripheral vascular, general surgery, and other life-saving applications.
“The launch of our ePTFE platform and CDMO services is a natural extension of MEI’s commitment to innovation, quality, and global collaboration,” said Tony Liu, CEO of MedEdge Innovations. “Through www.meimedtech.com, we are making our high-performance ePTFE materials more accessible to medical device innovators seeking reliability, scalability, and customization.”
Key Highlights of MEI’s ePTFE and CDMO Capabilities:
With the new platform, MEI aims to become a go-to partner for medical technology companies seeking biomaterials with superior durability, flexibility, and biocompatibility for both R&D and large-scale production.
To learn more about MEI’s ePTFE technologies and CDMO service offerings or to initiate a project consultation, visit www.meimedtech.com.
About MedEdge Innovations
MedEdge Innovations (MEI) is a forward-thinking medical technology company specializing in the development of advanced materials and devices that improve patient outcomes. With a strong foundation in proprietary platforms and R&D, MEI empowers next-generation medical innovation for global markets.
Website: www.meimedtech.com
SOURCE MEI Medical Technologies Co., Ltd.
Vancouver, British Columbia--(Newsfile Corp. - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF)…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
This groundbreaking discovery has revealed a systemic metabolic dysfunction that creates a toxic exosome cargo…
Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint…
Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…